Cargando…
Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis
Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis. Lupus nephritis is a major complication of systemic lupus erythematosus (SLE) that can lead to significant illness or even d...
Autores principales: | Frieri, Marianne, Heuser, William, Bliss, Joshua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419251/ https://www.ncbi.nlm.nih.gov/pubmed/25969652 http://dx.doi.org/10.4103/0976-500X.155482 |
Ejemplares similares
-
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
por: Plüß, Marlene, et al.
Publicado: (2022) -
De novo lupus nephritis during treatment with belimumab
por: Parodis, Ioannis, et al.
Publicado: (2020) -
Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis
por: Zhang, Han, et al.
Publicado: (2023) -
Efficacy of belimumab monotherapy in high infectious risk patient affected by lupus nephritis
por: D’Alessandro, Roberto, et al.
Publicado: (2021) -
Treatment Using Both Voclosporin and Belimumab in Four Patients With Lupus Nephritis
por: Baum, Rebecca, et al.
Publicado: (2023)